Roche Holding, the Swiss pharmaceutical giant, said on Thursday that its group sales rose by 7% in the first quarter to 14.4 ...

Swiss drugmaker Roche is petitioning the U.S. government in direct talks for import tariff exemptions, arguing the products ...

Swiss drugmaker Roche said on Thursday its first-quarter sales rose a forecast-beating 7% driven by breast cancer drug Phesgo ...

Roche is working to mitigate potential impacts from tariffs by moving production of its medicines to the U.S. and petitioning ...

Roche (RHHBY) expects an increase in Group sales in the mid single digit range at CER. Core earnings per share are targeted to develop in the ...

Roche posted higher sales that beat analysts’ expectations on higher demand for its key drugs.

Sanofi (SNY) stock and Roche (RHHBY) stock trade flat after the duo reaffirmed 2025 forecasts despite strong Q1 results. Read ...

Swiss pharma giant Roche (ROG: SIX) today reported that it achieved sales growth of 6% (7% in francs) to 15.4 billion francs ...

RHHBY records impressive first-quarter 2025 performance on the back of strong demand for key drugs. The company confirms 2025 guidance.

Two of Europe’s biggest drugmakers said they’re looking at ways to protect themselves from US President Donald Trump’s potential tariffs.

The Swiss pharma giant made one of the most significant financial promises to bolster its domestic manufacturing capabilities as the Trump administration weighs levying tariffs on drugmakers.

Investing.com -- Roche on Thursday reported a 6% increase in group sales for the first quarter of 2025, driven by strong ...